Elevated bile acids are associated with left ventricular structural changes in biliary atresia.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
09
10
2022
accepted:
09
02
2023
medline:
18
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
epublish
Résumé
In children with biliary atresia (BA), pathologic structural changes within the heart, which define cirrhotic cardiomyopathy, are associated with adverse perioperative outcomes. Despite their clinical relevance, little is known about the pathogenesis and triggers of pathologic remodeling. Bile acid excess causes cardiomyopathy in experimental cirrhosis, but its role in BA is poorly understood. Echocardiographic parameters of left ventricular (LV) geometry [LV mass (LVM), LVM indexed to height, left atrial volume indexed to BSA (LAVI), and LV internal diameter (LVID)] were correlated with circulating serum bile acid concentrations in 40 children (52% female) with BA listed for transplantation. A receiver-operating characteristic curve was generated to determine optimal threshold values of bile acids to detect pathologic changes in LV geometry using Youden index. Paraffin-embedded human heart tissue was separately analyzed by immunohistochemistry for the presence of bile acid-sensing Takeda G-protein-coupled membrane receptor type 5. In the cohort, 52% (21/40) of children had abnormal LV geometry; the optimal bile acid concentration to detect this abnormality with 70% sensitivity and 64% specificity was 152 µmol/L (C-statistics=0.68). Children with bile acid concentrations >152 µmol/L had ∼8-fold increased odds of detecting abnormalities in LVM, LVM index, left atrial volume index, and LV internal diameter. Serum bile acids positively correlated with LVM, LVM index, and LV internal diameter. Separately, Takeda G-protein-coupled membrane receptor type 5 protein was detected in myocardial vasculature and cardiomyocytes on immunohistochemistry. This association highlights the unique role of bile acids as one of the targetable potential triggers for myocardial structural changes in BA.
Sections du résumé
BACKGROUND
In children with biliary atresia (BA), pathologic structural changes within the heart, which define cirrhotic cardiomyopathy, are associated with adverse perioperative outcomes. Despite their clinical relevance, little is known about the pathogenesis and triggers of pathologic remodeling. Bile acid excess causes cardiomyopathy in experimental cirrhosis, but its role in BA is poorly understood.
METHODS
Echocardiographic parameters of left ventricular (LV) geometry [LV mass (LVM), LVM indexed to height, left atrial volume indexed to BSA (LAVI), and LV internal diameter (LVID)] were correlated with circulating serum bile acid concentrations in 40 children (52% female) with BA listed for transplantation. A receiver-operating characteristic curve was generated to determine optimal threshold values of bile acids to detect pathologic changes in LV geometry using Youden index. Paraffin-embedded human heart tissue was separately analyzed by immunohistochemistry for the presence of bile acid-sensing Takeda G-protein-coupled membrane receptor type 5.
RESULTS
In the cohort, 52% (21/40) of children had abnormal LV geometry; the optimal bile acid concentration to detect this abnormality with 70% sensitivity and 64% specificity was 152 µmol/L (C-statistics=0.68). Children with bile acid concentrations >152 µmol/L had ∼8-fold increased odds of detecting abnormalities in LVM, LVM index, left atrial volume index, and LV internal diameter. Serum bile acids positively correlated with LVM, LVM index, and LV internal diameter. Separately, Takeda G-protein-coupled membrane receptor type 5 protein was detected in myocardial vasculature and cardiomyocytes on immunohistochemistry.
CONCLUSION
This association highlights the unique role of bile acids as one of the targetable potential triggers for myocardial structural changes in BA.
Identifiants
pubmed: 37058680
doi: 10.1097/HC9.0000000000000109
pii: 02009842-202305010-00008
pmc: PMC10109457
pii:
doi:
Substances chimiques
Bile Acids and Salts
0
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020;71:334–45.
Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl. 2021;27:876–886.
Desai MS, Zainuer S, Kennedy C, Kearney D, Goss J, Karpen SJ. Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation. Gastroenterology. 2011;141:1264–72.
Gorgis NM, Kennedy C, Lam F, Thompson K, Coss-Bu J, Arikan AA, et al. Clinical consequences of cardiomyopathy in children with biliary atresia requiring liver transplantation. Hepatology. 2019;69:1206–18.
Jang DM, Jun IG, Moon YJ, Shin WJ, Song JG, Hwang GS. Pretransplant left ventricular dysfunction adversely affects perioperative outcomes in pediatric liver transplantation: a retrospective observational study. Transplant Proc. 2016;48:3328–35.
Junge N, Junge C, Schroder J, Pfister ED, Leiskau C, Hohmann D, et al. Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes. Liver Transpl. 2018;24:820–30.
Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol. 2006;3:329–37.
Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177–86.
Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009;3:294–304.
Yoon KT, Liu H, Lee SS. Cirrhotic cardiomyopathy. Curr Gastroenterol Rep. 2020;22:45.
Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassel BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol. 2010;56:539–49.
Morrison J, Ferguson E, Figueroa J, Karpen SJ. Features of cirrhotic cardiomyopathy early in the lives of infants with biliary atresia correlate with outcomes following kasai portoenterostomy. Hepatol Commun. 2022. doi:10.1002/hep4.1890
doi: 10.1002/hep4.1890
Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid receptor TGR5—connecting nutrition and metabolism. Thyroid. 2008;18:167–74.
Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50:1509–20.
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484–9.
Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem. 2022;636:114388.
Bashour TT, Antonini C Sr, Fisher J. Severe sinus node dysfunction in obstructive jaundice. Ann Intern Med. 1985;103:384–5.
Rainer PP, Primessnig U, Harenkamp S, Doleschal B, Wallner M, Fauler G, et al. Bile acids induce arrhythmias in human atrial myocardium—implications for altered serum bile acid composition in patients with atrial fibrillation. Heart. 2013;99:1685–92.
Voiosu AM, Wiese S, Voiosu TA, Hove J, Bendtsen F, Moller S. Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2018;30:392–7.
Vasavan T, Deepak S, Jayawardane IA, Lucchini M, Martin C, Geenes V, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. J Hepatol. 2021;74:1087–96.
Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020;14:677–89.
Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;53:307–12.
Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23:465–95.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.
Bass LM, Shneider BL, Henn L, Goodrich NP, Magee JC. Clinically evident portal hypertension: an operational research definition for future investigations in the pediatric population. J Pediatr Gastroenterol Nutr. 2019;68:763–77.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.
Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30:1772–7.
Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A, et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology. 2010;51:2097–107.
Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435–40.
Keitel V, Spomer L, Marin JJ, Williamson C, Geenes V, Kubitz R, et al. Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta. 2013;34:810–6.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.
Harpavat S, Hawthorne K, Setchell KDR, Narvaez RM, Henn L, Beil CA, et al. Serum bile acids as a new prognostic biomarker in biliary atresia following kasai portoenterostomy. Hepatology. 2022;77:862–73.
Khurana S, Raufman JP, Pallone TL. Bile acids regulate cardiovascular function. Clin Transl Sci. 2011;4:210–8.
Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, Williamson C. Heart and bile acids—clinical consequences of altered bile acid metabolism. Biochim Biophys Acta. 2018;1864(pt B):1345–55.
Voiosu A, Wiese S, Voiosu T, Bendtsen F, Moller S. Bile acids and cardiovascular function in cirrhosis. Liver Int. 2017;37:1420–30.
Desai MS, Eblimit Z, Thevananther S, Kosters A, Moore DD, Penny DJ, et al. Cardiomyopathy reverses with recovery of liver injury, cholestasis and cholanemia in mouse model of biliary fibrosis. Liver Int. 2015;35:1464–77.
Desai MS, Mathur B, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen SJ, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology. 2017;65:189–201.
Williamson C, Miragoli M, Sheikh Abdul KS, Abu-Hayyeh S, Papacleovoulou G, Geenes V, et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis. 2011;29:58–61.
Lieb W, Gona P, Larson MG, Aragam J, Zile MR, Cheng S, et al. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014;7:870–88.
Ristow B, Ali S, Whooley MA, Schiller NB. Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study). Am J Cardiol. 2008;102:70–6.
Alis D, Asmakutlu O, Topel C, Karaarslan E. Diagnostic value of left atrial strain in pediatric hypertrophic cardiomyopathy with normal maximum left atrial volume index: preliminary cardiac magnetic resonance study. Pediatr Radiol. 2021;51:594–604.
Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile acids, liver cirrhosis, and extrahepatic vascular dysfunction. Front Physiol. 2021;12:718783.
Tiwari A, Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today. 2009;14:523–30.
Akcan AA, Srivaths P, Himes RW, Tufan PN, Lam F, Nguyen T, et al. Hybrid extracorporeal therapies as a bridge to pediatric liver transplantation. Pediatr Crit Care Med. 2018;19:e342–9.